Genotyping of six clopidogrel-metabolizing enzyme polymorphisms has a minor role in the assessment of platelet reactivity in patients with acute coronary syndrome
- PMID: 28179614
- PMCID: PMC5469111
- DOI: 10.14744/AnatolJCardiol.2016.7390
Genotyping of six clopidogrel-metabolizing enzyme polymorphisms has a minor role in the assessment of platelet reactivity in patients with acute coronary syndrome
Abstract
Objective: To evaluate the contribution of six polymorphisms to the platelet reactivity in patients with acute coronary syndrome (ACS) treated with clopidogrel.
Methods: Cross-sectional study of 278 consecutive patients with ACS. Detailed clinical information for each patient was collected and genotypes (CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C19*17, CYP3A4*1B, and PON1-Q192R) were evaluated with TaqMan® and KASPar® assays. Platelet reactivity was measured with VerifyNow®.
Results: Mean age of patients was 66±11 years and 182 (65.5%) patients presented ACS without ST-segment elevation. A total of 206 (74.1%) patients presented poor response to clopidogrel (PRC). CYP2C19*2 polymorphism (p=0.038) was associated with PRC in the univariate setting. In the multiple logistic regression analysis, the risk factors for PRC were the presence of CYP3A4*1B allele (odds ratio [OR] 4.03; 95% confidence interval [CI] 1.01-16.34), age (OR 1.43; 95% CI 1.03-2.00), and body mass index (OR 4.05; 95% CI 1.21-13.43), whereas elevated hemoglobin was a protective factor. Discrimination of PRC through the model that included the six polymorphisms added modest information to the model based on clinical variables (C statistic difference 3.9%).
Conclusion: CYP3A4*1B allele may be an independent determinant of PRC in patients with ACS, although the variability in response to clopidogrel explained by the six polymorphisms is poor when compared to clinical variables.
Conflict of interest statement
Figures



Similar articles
-
[Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].Med Clin (Barc). 2014 Jul 7;143(1):6-12. doi: 10.1016/j.medcli.2013.04.042. Epub 2013 Jul 10. Med Clin (Barc). 2014. PMID: 23850044 Spanish.
-
The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.Scand J Clin Lab Invest. 2015 May;75(3):223-9. doi: 10.3109/00365513.2014.993696. Epub 2015 Jan 16. Scand J Clin Lab Invest. 2015. PMID: 25594796
-
Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype?Eur J Clin Pharmacol. 2018 Dec;74(12):1567-1574. doi: 10.1007/s00228-018-2530-5. Epub 2018 Aug 3. Eur J Clin Pharmacol. 2018. PMID: 30073432
-
Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS.Thromb Res. 2017 Sep;157:97-102. doi: 10.1016/j.thromres.2017.07.011. Epub 2017 Jul 13. Thromb Res. 2017. PMID: 28734158
-
Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?Expert Rev Cardiovasc Ther. 2018 May;16(5):369-377. doi: 10.1080/14779072.2018.1459186. Epub 2018 Apr 3. Expert Rev Cardiovasc Ther. 2018. PMID: 29589775 Review.
Cited by
-
Study of the allelic variants CYP2C9*2 and CYP2C9*3 in samples of the Peruvian mestizo population.Biomedica. 2019 Sep 1;39(3):601-610. doi: 10.7705/biomedica.4636. Biomedica. 2019. PMID: 31584773 Free PMC article. English, Spanish.
References
-
- Jin HY, Yang TH, Kim DI, Chung SR, Seo JS, Jang JS, et al. High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting. Int J Cardiol. 2013;167:1877–81. - PubMed
-
- Park JJ, Park KW, Kang J, Jeon KH, Kang SH, Ahn HS, et al. Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents. Int J Cardiol. 2013;163:79–86. - PubMed
-
- Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–62. - PubMed
-
- Ko YG, Suh JW, Kim BH, Lee CJ, Kim JS, Choi D, et al. Comparison of 2 point-of-care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention. Am Heart J. 2011;161:383–90. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous